Genta, SkyePharma deal

Genta Jago Technologies B.V., a joint venture between GNTA and Jagotec AG, reached agreement in principle with SkyePharma's Krypton Ltd. subsidiary under which Genta Jago would grant Krypton an option to obtain a sublicense to develop and commercialize an improved version of a currently marketed sustained-release product. Genta Jago also would sublicense to Krypton the right to develop and commercialize generic formulations of five extended-release products, including Covera HS (verapamil), Voltaren XR (diclofenac) and Naprelan (naproxen). ...